Oncimmune Holdings Plc, an early cancer detection company, develops and commercializes products to diagnose cancer in the United Kingdom and North America.
The last earnings update was 67 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Oncimmune Holdings. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Oncimmune Holdings's earnings available for a low price, and how does
this compare to other companies in the same industry?
Oncimmune Holdings is not considered high growth as it is expected to be loss making for the next 1-3 years.
Oncimmune Holdings's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Oncimmune Holdings's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Oncimmune Holdings's finances.
The net worth of a company is the difference between its assets and liabilities.
Oncimmune Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Oncimmune Holdings has no long term commitments.
This treemap shows a more detailed breakdown of
Oncimmune Holdings's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Oncimmune Holdings has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Adam Mark Hill, MB, PhD, has been the Chief Executive Officer at Oncimmune Holdings Plc since September 2018. Dr. Mark also served as Director at Oncimmune Holdings Plc. He served as Chief Medical Officer and Chief Strategy Officer of Oncimmune Holdings Plc since April 9, 2018 until September 2018. He is a dual-qualified Clinician and Engineer, with a career built in industry, academia and practising medicine. During his career, he has held Chief Medical Officer and other senior management roles at private and listed companies, supplemented by advisory and government policy appointments. Most recently, he was Chief Medical Officer and later Chief Strategy Officer of McLaren Applied Technologies. He developed a Digital Therapeutics strategy and grew a team of experienced professionals across Commercial, Product, Programme, Quality and Technical disciplines to deliver against it. Previously, he was Chief Medical Officer at Sectra AB, the listed medical technology and encryption Communications Company, and a Management Consultant with PA Consulting. He graduated from Imperial College London as a Medical Doctor, whilst also earning a PhD in Engineering, attending Imperial College Business School, and the Royal Military Academy Sandhurst. He received his postgraduate clinical training from the Royal College of Surgeons of England, and professional engineering qualification from the Institution of Mechanical Engineers. He has built a portfolio of over 100 academic peer-reviewed, policy and popular-media publications. Currently, he is both a Visiting Professor in Global Health Innovation at Imperial College London, and sits on the Advisory Board of Imperial College Health Partners. Dr. Hill holds Doctor of Medicine, PhD Bioengineering and Bachelor of Science in Engineering. His Past Directorships include DON'T HESITATE TO COPE LIMITED &STRENSON MEDICAL LIMITED. He served as Chief Medical Officer of Sectra Aktiebolag (publ).
Insufficient data for Adam to compare compensation growth.
Adam's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The tenure for the Oncimmune Holdings management team is about average.
CEO & Director
Group Chief Financial Officer
Principal Scientist & Assistant Lab Director
General Counsel & Company Secretary
Chief Operational Scientist
Chief Medical Officer of US
Chief Commercial Officer of Asia
Senior Vice President of Market Access & Reimbursement Oncimmune (Usa)
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Oncimmune Holdings board of directors is less than 3 years, this suggests a new board.
Oncimmune Holdings Plc, an early cancer detection company, develops and commercializes products to diagnose cancer in the United Kingdom and North America. The company engages in the development of autoantibody based platform to allow cancer detection to a range of solid cancer tumor types. It offers EarlyCDT-Lung, a blood test, which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. The company also develops EarlyCDT-Liver to aid in the detection and confirmation of hepatocellular carcinoma (HCC) in high-risk patients with liver lesions of all sizes tests for liver cancer. Oncimmune Holdings Plc was incorporated in 2015 and is headquartered in Nottingham, the United Kingdom.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.